NCT07722741 — Geneos Therapeutics neoantigen vaccine trial
Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC
Registry record
| Registry ID | NCT07722741 ↗ |
|---|---|
| Lead sponsor | Geneos Therapeutics |
| Collaborators | — |
| Phase | Phase 2 |
| Status | Recruiting |
| Indication | HCC |
| Enrollment | 90 participants (target) |
| Start date | 2026-09 |
| Primary completion | 2029-09 (est.) |
| Last registry update | 4 Sept 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07722741), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07722741?
NCT07722741 (Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC) is registered on ClinicalTrials.gov as Phase 2, sponsored by Geneos Therapeutics.
Is NCT07722741 recruiting?
As of the 2026-09-04 registry update, NCT07722741 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07722741?
The lead sponsor is Geneos Therapeutics.
What condition does NCT07722741 study?
The registered condition is HCC. Primary completion is listed as 2029-09 (estimated).
Are results available for NCT07722741?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07722741.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.